Delving into the Latest Updates on BC0305 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Shandong Danhong Pharmaceutical Co., Ltd.

Active Organization

Shandong Danhong Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价健康受试者单剂量口服 BC0305 胶囊的安全性和耐受性，为该药多剂量临床试验方案的制定提供参考依据。次要目的：评价健康受试者单剂量口服 BC0305 胶囊的药代动力学和药效学特征。评价 BC0305 胶囊给药在体内的代谢产物，及主要代谢产物的 PK 特征（如适用）。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single oral dose of BC0305 capsules in healthy subjects, and to provide a reference for the formulation of a multi-dose clinical trial protocol for the drug. Secondary objective: To evaluate the pharmacokinetic and pharmacodynamic characteristics of a single oral dose of BC0305 capsules in healthy subjects. To evaluate the metabolites of BC0305 capsules in vivo, and the PK characteristics of the main metabolites (if applicable).

Start Date18 Jul 2024

Sponsor / Collaborator

Shandong Danhong Pharmaceutical Co., Ltd.

100 Clinical Results associated with BC0305

Login to view more data

100 Translational Medicine associated with BC0305

Login to view more data

100 Patents (Medical) associated with BC0305

Login to view more data

100 Deals associated with BC0305

Login to view more data